Journal of Clinical Lipidology
Volume 3, Issue 2 , Pages 143-145 , April 2009

A patient with new-onset hypercholesterolemia

Received 27 October 2008 ,Accepted 17 January 2009.

References 

  1. Ghandehari H, Kamal-Bahl S, Wong ND. Prevalence and extent of dyslipidemia and recommended lipid levels in US adults with and without cardiovascular comorbidities: the National Health and Nutrition Examination Survey 2003—2004. Am Heart J. 2008;156:112–119
  2. Durrington P. Dyslipidaemia. Lancet. 2003;362:717–731
  3. Tsimihodimos V, Dounousi E, Siamopoulos KC. Dyslipidemia in chronic kidney disease: an approach to pathogenesis and treatment. Am J Nephrol. 2008;28:958–973
  4. Kronenberg F. Dyslipidemia and nephrotic syndrome: recent advances. J Ren Nutr. 2005;15:195–203
  5. Orth SR, Ritz E. The nephrotic syndrome. N Engl J Med. 1998;338:1202–1211
  6. Gertz MA, Lacy MQ, Dispenzieri A. Amyloidosis. Hematol Oncol Clin North Am. 1999;13:1211–1233
  7. Bahlis NJ, Lazarus HM. Multiple myeloma-associated AL amyloidosis: is a distinctive therapeutic approach warranted?. Bone Marrow Transplant. 2006;38:7–15
  8. Feingold KR, Castro GR, Ishikawa Y, Fielding PE, Fielding CJ. Cutaneous xanthoma in association with paraproteinemia in the absence of hyperlipidemia. J Clin Invest. 1989;83:796–802
  9. Nozaki S, Ito Y, Nakagawa T, Yamashita S, Sasaki J, Matsuzawa Y. Autoimmune hyperlipidemia with inhibitory monoclonal antibodies against low density lipoprotein binding to fibroblasts in a case with multiple myeloma. Intern Med. 1997;36:920–925
  10. Fukudome K, Kato J, Ohashi T, Yamamoto Y, Eto T. Hyperlipidemia associated with multiple myeloma. Intern Med. 1996;35:337–340
  11. Kilgore LL, Patterson BW, Parenti DM, Fisher WR. Immune complex hyperlipidemia induced by an apolipoprotein-reactive immunoglobulin A paraprotein from a patient with multiple myeloma. Characterization of this immunoglobulin. J Clin Invest. 1985;76:225–232
  12. Cortese C, Lewis B, Miller NE, et al. Myelomatosis with type III hyperlipoproteinemia: clinical and metabolic studies. N Engl J Med. 1982;307:79–83
  13. Glueck CJ, Kaplan AP, Levy RI, et al. A new mechanism of exogenous hyperglyceridemia. Ann Intern Med. 1969;71:1051–1062
  14. Cengiz K, Bakan A, Yilmaz H. Lipoprotein abnormalities in patients with secondary renal amyloidosis. Int Urol Nephrol. 2001;32:615–619

 Conflicts of interest: The authors have no conflicts of interest.

PII: S1933-2874(09)00022-1

doi: 10.1016/j.jacl.2009.01.001

Journal of Clinical Lipidology
Volume 3, Issue 2 , Pages 143-145 , April 2009

Article Tools

* Image Usage & Resolution